Claims for Patent: 4,070,462

Summary for Patent: 4,070,462

Title:	Steroid ointment
Abstract:	An improved ointment for the topical administration of steroids is comprised of a therapeutically effective amount of a 17-mono or 17,21-diester of betamethasone in a non-aqueous base comprised of 5-15% of a glycol solvent, 1-3% of a principle emulsifying agent; 0-7% of a secondary emulsifying agent; and 70-90% of a petrolatum base.
Inventor(s):	Ecker; Varda (New York, NY)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	05/735,854
Patent Claims:	1. A method of treating inflammation which comprises applying to the skin a topical formulation comprising an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising - 15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum. 2. The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17,21-dipropionate. 3. The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone valerate. 4. The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is present in an amount of 0.01-0.2% by weight. 5. The method of claim 1 wherein the glycol solvent is 1,2-propylenediol. 6. The method of claim 1 wherein the wax is white wax. 7. A topical ointment for the treatment of inflammation which comprises an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising 5-15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum. 8. The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17,21-dipropionate. 9. The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17-valerate. 10. The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is present in an amount of 0.01-0.02% by weight. 11. The ointment of claim 7 wherein the glycol solvent is 1,2-propylenediol. 12. The ointment of claim 7 wherein the wax is white wax. 13. A method of treating psoriasis which comprises applying to the skin an ointment of claim 7. 14. A method of treating psoriasis which comprises applying to the skin an ointment of claim 8. 15. A method of treating psoriasis which comprises applying to the skin an ointment of claim 9. 16. A method of treating psoriasis which comprises applying to the skin an ointment of claim 10. 17. A method of treating psoriasis which comprises applying to the skin an ointment of claim 11. 18. A method of treating psoriasis which comprises applying to the skin an ointment of claim 12.